Medicinal Products

368. Deputy Ken O'Flynn asked the Minister for Health which body holds ultimate accountability for ensuring continuity of supply of clinically critical medicines at national level; and the oversight mechanisms in place to monitor performance against this responsibility. [27522/26]

369. Deputy Ken O'Flynn asked the Minister for Health the preparatory steps that have been taken to align national policy with the forthcoming European Union list of critical medicines; and whether an interim national list is in operation pending the introduction of EU measures. [27523/26]

2626. Deputy George Lawlor asked the Minister for Health the current position regarding her Department's discussions with the IPU in relation to the charging of GMS patients for the provision of MDS/Blister packs; her views on whether that providing required medication in blister packs to vulnerable patients is an essential health service to ensure proper dosage is received and to avoid overdosing…

2769. Deputy Richard Boyd Barrett asked the Minister for Health for an update on the approval of omaveloxolone for the treatment of Friedrich's ataxia. [24114/26]

2936. Deputy Paula Butterly asked the Minister for Health to respond to correspondence (details supplied) regarding the application of charges for blister packs, noting that phased dispensing is essential for patient safety; and if she will make a statement on the matter. [24861/26]

2985. Deputy Denise Mitchell asked the Minister for Health if consideration will be given to adding the drug skyclarys which is used in the treatment of Friedreich's ataxia to the drugs payment scheme; and if she will make a statement on the matter. [25182/26]

2994. Deputy Edward Timmins asked the Minister for Health the steps that can be taken to bring Ireland in line with other European countries for the treatment of Friedreich’s ataxia (details supplied); and if she will make a statement on the matter. [25231/26]

2996. Deputy Aindrias Moynihan asked the Minister for Health for clarification on the stage of a medication (details supplied) under assessment to be included on the drugs payment scheme; and if she will make a statement on the matter. [25240/26]

3016. Deputy Réada Cronin asked the Minister for Health if consideration will be given to adding Libre 2 PLUs patches to the long-term illness scheme for those transitioning from type 2 to type 1 diabetes; and if she will make a statement on the matter. [25382/26]

3068. Deputy Cathy Bennett asked the Minister for Health if her attention has been drawn to the use of the drug fampyra with regard to treating of ataxia within other EU member states; if consideration has been given to facilitating similar usage within Ireland; if so, the current status of any such considerations; the steps that a person can take to access fampyra for such treatment; and if she w…

3085. Deputy Cian O'Callaghan asked the Minister for Health if she is in favour of reimbursement pathways for GLP-1 therapies in obesity where clinically indicated; and if she will make a statement on the matter. [25785/26]

3138. Deputy Tom Brabazon asked the Minister for Health if the HSE will fund the skyclarys drug for those suffering from Friedreich's ataxia. [26084/26]

3160. Deputy Holly Cairns asked the Minister for Health if a decision not to reimburse a treatment Omaveloxolone sold under the brand name Skyclarys will be reviewed given it is the only pharmaceutical treatment available for treating Friedreich's Ataxia; and if she will make a statement on the matter. [26180/26]

3161. Deputy Thomas Gould asked the Minister for Health if there are any circumstances a person can be approved Saxenda on the drugs payment scheme without a prediabetic diagnosis. [26185/26]

3179. Deputy Naoise Ó Muirí asked the Minister for Health if her Department has considered reimbursement pathways for GLP-1 therapies in obesity where clinically indicated; and if she will make a statement on the matter. [26338/26]

3203. Deputy Peadar Tóibín asked the Minister for Health the plans to allow recipients of prescribed medicinal cannabis in the North to legally carry and use their medicine in the State (details supplied). [26439/26]

3206. Deputy Pat Buckley asked the Minister for Health if she will ensure that the HSE urgently prioritizes a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for Friedreich's ataxia, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025-2030. [26466/26]

3207. Deputy Pat Buckley asked the Minister for Health her views on whether the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030. [26467/26]

3211. Deputy Ruth Coppinger asked the Minister for Health to prioritise the negotiations for reimbursement of a particular drug given that it is the only treatment for a specific disease (details supplied); and if she will make a statement on the matter. [26478/26]

3224. Deputy Ruth Coppinger asked the Minister for Health if she will take steps to ensure that skyclarys (omaveloxolone) is made available for those with Fredericks ataxia who require it; and if she will make a statement on the matter. [26512/26]

3237. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 685 of 19 February 2026, if she is committed to implementing Ava's protocol, recommended by Cork City Coroner's office in 2024; if this recommendation will be examined by the Review of Access to Cannabis for Medical Use; and if she will make a statement on the matter. [26568/26]

3239. Deputy Mairéad Farrell asked the Minister for Health further to Parliamentary Question No.1818 of 18 March 2026, if she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an 'unmet need' as outlined in the Natio…

3240. Deputy Mary Lou McDonald asked the Minister for Health the specific steps that are being taken to ensure the HSE considers the time-critical nature of the 2026 IPHA Framework Agreement during the current price negotiations for Skyclarys; and the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement, which aims for a 180-day decisio…

3347. Deputy Sean Fleming asked the Minister for Health to outline the process where a person has been on medication (details supplied) and requires specific medical services/medication for their condition; and if she will make a statement on the matter. [27003/26]

3358. Deputy Robert O'Donoghue asked the Minister for Health if she will intervene to ensure that the HSE urgently concludes reimbursement negotiations for skyclarys given that it is currently the only available treatment for Friedreich’s ataxia and that the condition may be considered an unmet need under the National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter.…